Abstract
Abstract Cancer immunotherapy is an exciting and active area of cancer research; and several new immunotherapies have been approved for treatment of melanoma and lung cancer. Moreover, in melanoma, treatment with these immunotherapeutic agents has shown to nearly double the survival rate of patients with metastatic disease. Additionally, in on-going clinical trials, immunotherapy is also showing promise in regards to both safety and effectiveness in other types of cancer including breast and ovarian. However, access to these new immunotherapies is not the same for all cancer patients. Within medically underserved populations there are various factors that prohibit cancer patients from receiving these new and promising therapies. This presentation will review current cancer immunotherapeutic agents, their effectiveness and cost, as well as the challenges around ensuring that all patients who would benefit from these agents have access to them. Citation Format: Lupe G. Salazar. Immunotherapy: Is it within everyone's reach? [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr IA25.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
